Eli Lilly and Company (LLY) Gets Downgraded to Reduce From Hold by HSBC – Here’s Why

Eli Lilly and Company (NYSE:LLY) is one of the best ethical companies to invest in now according to Reddit. Eli Lilly and Company (NYSE:LLY) was downgraded to Reduce from Hold by HSBC on March 17, with the firm bringing the price target on the stock down to $850 from $1,070. The firm told investors in a research note that it believes expectations for the total addressable market for obesity are elevated at over $150 billion, and the market is likely to be in the range of $80 billion -$120 billion by 2032, with price competition “ likely to be significant”.

HSBC also stated that Eli Lilly and Company’s (NYSE:LLY) obesity price cuts in 2026 are a headwind, with its guidance implying that it can continue to “defy gravity with volume growth.” The firm thinks that while access to anti-obesity medications may be expanded by the oral launch, the “compliance and persistence of these drugs might disappoint”, adding that it believes the oral drug launch expectations for Lilly are too high.

In a separate development, Reuters reported on March 11 that Eli Lilly and Company (NYSE:LLY) plans to invest $3 billion in China over the next decade, helping develop production capacity for its experimental ‌type-2 diabetes and obesity treatment orforglipron. In a statement delivered on WeChat, the company stated that it submitted a marketing application for orforglipron ​to China’s drug regulator at the end of ​2025.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.